MSLN and neoplasm: In animal models, the induction of anti-Mesothelin CD8+ T cell responses resulted in the reduction in tumour volume and prolonged survival in an orthotopic PC mouse model [33], [34], suggesting that MSLN is a tumour rejection antigen for pancreatic carcinoma.